Merck & Co. Stock Soars on Cancer Drug Progress

Merck & Co.'s stock has seen significant gains in recent times, trading at around $144.71 on the New York Stock Exchange as of September 10, 2026.

The company's progress with cancer drug development has led to analysts lifting their price targets for Merck & Co. stock. Berenberg raised its target to $137 from $127 while maintaining a Hold rating, citing new data.

Guggenheim also lifted its price target for Merck & Co. to $170 and kept a Buy rating after positive results from a cancer drug collaboration with Moderna.

Merck & Co.'s second-quarter 2026 earnings reported revenue of $16.61 billion, beating analyst expectations of $16.37 billion, with an increase of about 5.1% versus the same quarter a year earlier.